




RealRate

MEDICINAL PRODUCTS 2019

Chemours Co
Rank 27 of 50





MEDICINAL PRODUCTS 2019

Chemours Co
Rank 27 of 50



The relative strengths and weaknesses of Chemours Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemours Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Chemours Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 26%, being 32% points above the market average of -5.9%.

Input Variable	Value in 1000 USD
Assets, Current	3,293,000
Assets, Non-Current	597,000
General and Administrative Expense	5,324,000
Goodwill	0
Liabilities, Current	1,709,000
Liabilities, Non-Current	4,416,000
Other Assets	181,000
Other Compr. Net Income	-123,000
Other Expenses	403,000
Other Liabilities	217,000
Other Net Income	167,000
Other Revenues	6,638,000
Property, Plant and Equipment, Net	3,291,000
Research and Development	82,000

Output Variable	Value in 1000 USD
Liabilities	6,342,000
Assets	7,362,000
Expenses	5,809,000
Revenues	6,638,000
Stockholders Equity	1,020,000
Net Income	996,000
Comprehensive Net Income	934,500
Economic Capital Ratio	26%